Diligence memo · auto-generated · as of July 2, 2026

Agronomed Pharmaceuticals LLC

Agronomed Pharmaceuticals LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Agronomed Pharmaceuticals LLC operates in Biotech / Pharma, based in EXTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Agronomed Pharmaceuticals LLC has raised $9.2M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.9M on 2019-06-03.

Most recent recorded round closed around 2020-10-01.

Valuation (modeled)modeled

Provath models Agronomed Pharmaceuticals LLC at approximately $77M (range $1.6M–$567M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.28× the median modeled value of Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 14 months.

Last raise 5.7 yr ago; this sector typically re-raises about every 15 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.8× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 61% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 67% of those peers.

Closest niche peers: rMark Bio, Inc., Massive Bio, Inc., Light Bio, Inc., Cellix Biosciences, Inc., xD Bio, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.